Use left and right arrow keys to navigate between menu items.

Use escape to exit the menu.

The sudden death of Kyle Busch has drawn attention to a rare but devastating medical progression: when pneumonia escalates into fatal sepsis.

An ER doctor spoke with Fox News Digital about how sepsis can trigger a rapid health decline.

“Sepsis is actually not a specific disease or diagnosis, but rather the syndrome that occurs when the body has certain abnormal findings and a presumed infection,” said Dr. Kenneth J. Perry, a South Carolina-based emergency medicine physician.

HOW PNEUMONIA PROGRESSES TO SEPSIS: DOCTORS EXPLAIN AFTER KYLE BUSCH’S DEATH

The markers of sepsis include elevated white blood cell counts, a high or low temperature, and elevated heart and respiratory rates, according to Perry. Because of this, a patient with pneumonia is often already technically septic by definition.

While many people assume a worsening infection means bacteria are multiplying uncontrollably, it often has more to do with the body’s internal environment.

“It is often not the bacteria itself that is causing the specific decline,” Perry said. “In most cases, it is a cascade of inflammatory processes that are set in motion by the infection.”

When this inflammation spirals out of control, the body moves from having a manageable infection into severe sepsis. This is when otherwise healthy people can rapidly deteriorate.

SURGE IN WALKING PNEUMONIA AFFECTS THESE HIGH-RISK GROUPS, SAYS DR. MARC SIEGEL

“The concerning thing that can happen with any individual … is that sepsis can then lead to low blood pressure, worsening vital signs and organ damage,” Perry said.

“As multiple organs fail, it becomes very difficult for the medical team to treat and can sometimes lead ultimately to death.”

It is very unlikely to have pneumonia and not have any symptoms, according to Perry. Early signs can mimic a severe flu, including fevers, chills, a productive cough, and chest or back pain in cases where the lung is infected.

When sepsis begins to take hold, time becomes the most critical factor. “We have known for a number of years that early antibiotic therapy is beneficial in the treatment of sepsis,” Perry said.

CLICK HERE FOR MORE HEALTH STORIES

If you or a loved one are managing an infection at home, the doctor says the following red flags mean you should bypass the clinic and head straight to the emergency room.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

• Shortness of breath or difficulty breathing
• A racing heart rate or fever that continues to worsen even after starting treatment
• Severe chest pain associated with a productive cough

While cases like Busch’s are tragic, Perry stressed that this shouldn’t cause widespread panic. Most patients with pneumonia do very well with standard oral antibiotics.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

The NASCAR star’s rapid decline underscores the importance of medical vigilance and “having a primary care physician with whom you have a good relationship,” according to the ER doctor.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

“Monitoring symptoms while having easy access to primary care is a very beneficial and appropriate plan for most patients,” he added.

Popular glucagon-like peptide-1 (GLP-1) weight-loss drugs may help slow the spread of some cancers, according to new research to be presented at a major medical conference.

Research led by Cleveland Clinic found that the medications may reduce the spread of several obesity-related cancers, including lung, breast, colorectal and liver cancers.

The findings will be presented at the 2026 ASCO Annual Meeting next week in Chicago.

WEIGHT-LOSS DRUGS NOW LINKED TO CANCER PROTECTION IN WOMEN, MAJOR NEW STUDY REVEALS

According to a press release, the real-world retrospective study included 12,112 patients with the following types of obesity-related cancers, ranging from stage 1 to stage 3.

• Breast adenocarcinoma
• Prostate adenocarcinoma
• Non-small cell lung cancer (NSCLC)
• Colorectal adenocarcinoma
• Hepatocellular carcinoma (liver cancer)
• Renal cell carcinoma
• Pancreatic adenocarcinoma

Half of the participants started a GLP-1 medication – semaglutide, tirzepatide, dulaglutide, liraglutide, lixisenatide or pramlintide – after their cancer diagnosis.

The other half began taking a DPP-4 inhibitor comparator “gliptins,” a different class of diabetes medications, the study noted.

WEIGHT-LOSS DRUGS’ IMPACT ON CANCER RISK REVEALED IN NEW STUDY

Compared to the patients taking gliptins, the GLP-1 users were found to have significantly lower progression to stage 4 disease for four types of cancers.

The biggest risk reduction was for non-small cell lung cancer (50%), followed by breast cancer (43%), colorectal cancer (31%) and liver cancer (38%).

“Our study found that use of GLP-1 drugs, compared to DPP-4 inhibitors and other antidiabetic drugs, was associated with a meaningful reduction in cancer progression across four solid tumor types,” said lead study author Mark David Orland, MD, of the Taussig Cancer Institute at Cleveland Clinic, in the release. “It provides early evidence that future studies are worth pursuing.”

CLICK HERE FOR MORE HEALTH STORIES

Three other types of cancer – prostate, pancreatic and kidney – also had lower rates of spread among those taking GLP-1s, but those differences were “not statistically significant,” the researchers noted.

“Our study found that use of GLP-1 drugs … was associated with a meaningful reduction in cancer progression across four solid tumor types.”

Tumors with higher levels of GLP-1 receptors — proteins that help cells respond to GLP-1 hormones and drugs — were also linked to better survival outcomes, according to the study findings.

Overall, patients whose tumors had more of these receptors were about one-third less likely to die during the study period.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The incidence of adverse side effects was similar between GLP-1 and gliptin groups.

The findings suggest that GLP-1 pathways may directly influence how some cancers grow or spread, though researchers say more studies are needed to understand the mechanism behind this effect.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

The study, which has not yet been peer-reviewed, had some limitations, according to the researchers. As it was retrospective and observational in design – as opposed to a randomized clinical trial – it couldn’t prove that GLP-1 drugs directly prevent cancer progression.

Other factors, such as participants’ health conditions, weight loss and metabolic improvements, may have influenced the results, researchers noted.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

For some specific cancer types, there may not have been enough patients represented to detect statistically significant differences.

Further randomized clinical trials are needed to evaluate these preliminary findings and to determine the specific ways in which GLP-1s control cancer progression.